The report notes that the drug has passed the registration procedure, which is used in the event of an emergency. Such a vaccine can only be used in medical institutions that are eligible for such procedures.

It remains unknown how long immunity from coronavirus lasts because the studies were not extensive enough and were carried out on a tight schedule.

“The protective titer (the limiting dilution of a blood serum sample at which the activity of antibodies is detected) is currently unknown. The duration of protection is unknown. Clinical studies on epidemiological efficacy have not been conducted.” – excerpt from the documents of the Gamaleya Center.

The publication notes that after 42 days of vaccination, the volunteers recorded an antibody index with an average titer of 49.3. This value is stated to be lower than the average antibody level and may decline over time.

According to the country’s Ministry of Health, The vaccine is able to form a stable immunity, which must be maintained for two years. However, a professor of pathophysiology at the First Moscow State Medical University, Sechenov’s Anton Ershov points out that there is no confirmation of these statements.

The Gamaleya Center also reports that side effects in people who have been vaccinated are “frequent and very common.”

Is the vaccine safe?

Documents of the Gamaleya Center, formed on the basis of an open clinical study of the safety, tolerability and immunogenicity of the drug, the thesis about the absence of external manifestations and side effects cannot be confirmed. Experts have acknowledged that undesirable events in the frequency of occurrence “can be regarded as occurring often and very often.”

In 38 subjects, 144 undesirable phenomena were recorded. Most passed without consequences. However, on the 42nd day of the study, 31 undesirable appearances were not completed (laboratory abnormalities of immunological indicators were registered). The outcome of 27 NIA to the developer is still unknown, it follows from the documents.

Volunteers after vaccination were marked with swelling, pain, hyperthermia and itching. Among the common manifestations – asthenia, malaise, pyrexia, fever, decreased appetite, headache, diarrhoea, oropharyngeal pain, nasal congestion, sore throat, Rhinorrhea.

Indications for use

Medical records show that the vaccine has an age limit of 18-60. This is again due to the narrowness of the research. Children and pensioners are not allowed the drug.

It is not suitable for pregnant and nursing, as “efficiency and safety have not been studied.” The interaction of the vaccine with other drugs and its effect on the ability to drive was also not investigated.

The drug should be used with caution in chronic kidney and liver diseases, diabetes, severe diseases of the blood system, epilepsy, strokes, cardiovascular diseases, immunodeficiency, autoimmune diseases, allergic reactions, eczema.